Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma

AIM:To investigate whether expression of cancer stem cell(CSC)markers is associated with recurrence and survival in hepatocellular carcinoma(HCC)patients.METHODS:A consecutive series of 90 HCC patients who underwent curative hepatectomy between April2007 and April 2009 were analyzed.Of the 90 patien...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 20; no. 8; pp. 2098 - 2106
Main Author Guo, Zhe
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Co., Limited 28.02.2014
Subjects
Online AccessGet full text

Cover

Loading…
Abstract AIM:To investigate whether expression of cancer stem cell(CSC)markers is associated with recurrence and survival in hepatocellular carcinoma(HCC)patients.METHODS:A consecutive series of 90 HCC patients who underwent curative hepatectomy between April2007 and April 2009 were analyzed.Of the 90 patients,38(42%)experienced recurrence within two years of surgery.To adjust for baseline differences between this early recurrence group and the other patients,propensity-score matching was used to generate 25 pairs of patients.Immunohistochemistry was used to compare expression of CD133,CD90,and epithelial cell adhesion molecule(EpCAM)in liver tissues from propensity score-matched patients and from 10 healthy adults.Associations of the three markers with HCC,clinicopathological characteristics,early recurrence,and survival time were explored.RESULTS:The expression of all three CSC markers was significantly higher in HCC tissue than in healthy liver tissue(P<0.001 for all).Among the HCC clinicopathology characteristics examined,the absence of tumor capsule was associated with CD133 expression(P=0.005);higher histopathology grade and larger tumor size were associated with CD90 expression(P=0.010 and 0.034,respectively);and elevated serum alpha-fetoprotein levels were associated with EpCAM expression(P=0.021).Expression of CD90 and EpCAM was significantly higher in the early recurrence group than in other patients(P=0.001 and 0.045,respectively),whereas CD133 expression was not significantly different between the two groups(P=0.440).Multivariate analysis identified only CD90 expression as significantly associated with early recurrence.Log-rank analysis identified expression of both CD90 and EpCAM as significantly associated with survival time of HCC patients.Cox regression identified EpCAM expression as an independent predictor of survival time.CONCLUSION:Expression of CD133,CD90,and EpCAM CSC markers may be linked to HCC tumor onset and/or progression.In addition,EpCAM expression is associated with shorter survival time,while CD90 expression is associated with early HCC recurrence.
AbstractList To investigate whether expression of cancer stem cell (CSC) markers is associated with recurrence and survival in hepatocellular carcinoma (HCC) patients. A consecutive series of 90 HCC patients who underwent curative hepatectomy between April 2007 and April 2009 were analyzed. Of the 90 patients, 38 (42%) experienced recurrence within two years of surgery. To adjust for baseline differences between this early recurrence group and the other patients, propensity-score matching was used to generate 25 pairs of patients. Immunohistochemistry was used to compare expression of CD133, CD90, and epithelial cell adhesion molecule (EpCAM) in liver tissues from propensity score-matched patients and from 10 healthy adults. Associations of the three markers with HCC, clinicopathological characteristics, early recurrence, and survival time were explored. The expression of all three CSC markers was significantly higher in HCC tissue than in healthy liver tissue (P < 0.001 for all). Among the HCC clinicopathology characteristics examined, the absence of tumor capsule was associated with CD133 expression (P = 0.005); higher histopathology grade and larger tumor size were associated with CD90 expression (P = 0.010 and 0.034, respectively); and elevated serum alpha-fetoprotein levels were associated with EpCAM expression (P = 0.021). Expression of CD90 and EpCAM was significantly higher in the early recurrence group than in other patients (P = 0.001 and 0.045, respectively), whereas CD133 expression was not significantly different between the two groups (P = 0.440). Multivariate analysis identified only CD90 expression as significantly associated with early recurrence. Log-rank analysis identified expression of both CD90 and EpCAM as significantly associated with survival time of HCC patients. Cox regression identified EpCAM expression as an independent predictor of survival time. Expression of CD133, CD90, and EpCAM CSC markers may be linked to HCC tumor onset and/or progression. In addition, EpCAM expression is associated with shorter survival time, while CD90 expression is associated with early HCC recurrence.
AIM: To investigate whether expression of cancer stem cell (CSC) markers is associated with recurrence and survival in hepatocellular carcinoma (HCC) patients. METHODS: A consecutive series of 90 HCC patients who underwent curative hepatectomy between April 2007 and April 2009 were analyzed. Of the 90 patients, 38 (42%) experienced recurrence within two years of surgery. To adjust for baseline differences between this early recurrence group and the other patients, propensity-score matching was used to generate 25 pairs of patients. Immunohistochemistry was used to compare expression of CD133, CD90, and epithelial cell adhesion molecule (EpCAM) in liver tissues from propensity score-matched patients and from 10 healthy adults. Associations of the three markers with HCC, clinicopathological characteristics, early recurrence, and survival time were explored. RESULTS: The expression of all three CSC markers was significantly higher in HCC tissue than in healthy liver tissue ( P < 0.001 for all). Among the HCC clinicopathology characteristics examined, the absence of tumor capsule was associated with CD133 expression ( P = 0.005); higher histopathology grade and larger tumor size were associated with CD90 expression ( P = 0.010 and 0.034, respectively); and elevated serum alpha-fetoprotein levels were associated with EpCAM expression ( P = 0.021). Expression of CD90 and EpCAM was significantly higher in the early recurrence group than in other patients ( P = 0.001 and 0.045, respectively), whereas CD133 expression was not significantly different between the two groups ( P = 0.440). Multivariate analysis identified only CD90 expression as significantly associated with early recurrence. Log-rank analysis identified expression of both CD90 and EpCAM as significantly associated with survival time of HCC patients. Cox regression identified EpCAM expression as an independent predictor of survival time. CONCLUSION: Expression of CD133, CD90, and EpCAM CSC markers may be linked to HCC tumor onset and/or progression. In addition, EpCAM expression is associated with shorter survival time, while CD90 expression is associated with early HCC recurrence.
AIM:To investigate whether expression of cancer stem cell(CSC)markers is associated with recurrence and survival in hepatocellular carcinoma(HCC)patients.METHODS:A consecutive series of 90 HCC patients who underwent curative hepatectomy between April2007 and April 2009 were analyzed.Of the 90 patients,38(42%)experienced recurrence within two years of surgery.To adjust for baseline differences between this early recurrence group and the other patients,propensity-score matching was used to generate 25 pairs of patients.Immunohistochemistry was used to compare expression of CD133,CD90,and epithelial cell adhesion molecule(EpCAM)in liver tissues from propensity score-matched patients and from 10 healthy adults.Associations of the three markers with HCC,clinicopathological characteristics,early recurrence,and survival time were explored.RESULTS:The expression of all three CSC markers was significantly higher in HCC tissue than in healthy liver tissue(P&lt;0.001 for all).Among the HCC clinicopathology characteristics examined,the absence of tumor capsule was associated with CD133 expression(P=0.005);higher histopathology grade and larger tumor size were associated with CD90 expression(P=0.010 and 0.034,respectively);and elevated serum alpha-fetoprotein levels were associated with EpCAM expression(P=0.021).Expression of CD90 and EpCAM was significantly higher in the early recurrence group than in other patients(P=0.001 and 0.045,respectively),whereas CD133 expression was not significantly different between the two groups(P=0.440).Multivariate analysis identified only CD90 expression as significantly associated with early recurrence.Log-rank analysis identified expression of both CD90 and EpCAM as significantly associated with survival time of HCC patients.Cox regression identified EpCAM expression as an independent predictor of survival time.CONCLUSION:Expression of CD133,CD90,and EpCAM CSC markers may be linked to HCC tumor onset and/or progression.In addition,EpCAM expression is associated with shorter survival time,while CD90 expression is associated with early HCC recurrence.
To investigate whether expression of cancer stem cell (CSC) markers is associated with recurrence and survival in hepatocellular carcinoma (HCC) patients.AIMTo investigate whether expression of cancer stem cell (CSC) markers is associated with recurrence and survival in hepatocellular carcinoma (HCC) patients.A consecutive series of 90 HCC patients who underwent curative hepatectomy between April 2007 and April 2009 were analyzed. Of the 90 patients, 38 (42%) experienced recurrence within two years of surgery. To adjust for baseline differences between this early recurrence group and the other patients, propensity-score matching was used to generate 25 pairs of patients. Immunohistochemistry was used to compare expression of CD133, CD90, and epithelial cell adhesion molecule (EpCAM) in liver tissues from propensity score-matched patients and from 10 healthy adults. Associations of the three markers with HCC, clinicopathological characteristics, early recurrence, and survival time were explored.METHODSA consecutive series of 90 HCC patients who underwent curative hepatectomy between April 2007 and April 2009 were analyzed. Of the 90 patients, 38 (42%) experienced recurrence within two years of surgery. To adjust for baseline differences between this early recurrence group and the other patients, propensity-score matching was used to generate 25 pairs of patients. Immunohistochemistry was used to compare expression of CD133, CD90, and epithelial cell adhesion molecule (EpCAM) in liver tissues from propensity score-matched patients and from 10 healthy adults. Associations of the three markers with HCC, clinicopathological characteristics, early recurrence, and survival time were explored.The expression of all three CSC markers was significantly higher in HCC tissue than in healthy liver tissue (P < 0.001 for all). Among the HCC clinicopathology characteristics examined, the absence of tumor capsule was associated with CD133 expression (P = 0.005); higher histopathology grade and larger tumor size were associated with CD90 expression (P = 0.010 and 0.034, respectively); and elevated serum alpha-fetoprotein levels were associated with EpCAM expression (P = 0.021). Expression of CD90 and EpCAM was significantly higher in the early recurrence group than in other patients (P = 0.001 and 0.045, respectively), whereas CD133 expression was not significantly different between the two groups (P = 0.440). Multivariate analysis identified only CD90 expression as significantly associated with early recurrence. Log-rank analysis identified expression of both CD90 and EpCAM as significantly associated with survival time of HCC patients. Cox regression identified EpCAM expression as an independent predictor of survival time.RESULTSThe expression of all three CSC markers was significantly higher in HCC tissue than in healthy liver tissue (P < 0.001 for all). Among the HCC clinicopathology characteristics examined, the absence of tumor capsule was associated with CD133 expression (P = 0.005); higher histopathology grade and larger tumor size were associated with CD90 expression (P = 0.010 and 0.034, respectively); and elevated serum alpha-fetoprotein levels were associated with EpCAM expression (P = 0.021). Expression of CD90 and EpCAM was significantly higher in the early recurrence group than in other patients (P = 0.001 and 0.045, respectively), whereas CD133 expression was not significantly different between the two groups (P = 0.440). Multivariate analysis identified only CD90 expression as significantly associated with early recurrence. Log-rank analysis identified expression of both CD90 and EpCAM as significantly associated with survival time of HCC patients. Cox regression identified EpCAM expression as an independent predictor of survival time.Expression of CD133, CD90, and EpCAM CSC markers may be linked to HCC tumor onset and/or progression. In addition, EpCAM expression is associated with shorter survival time, while CD90 expression is associated with early HCC recurrence.CONCLUSIONExpression of CD133, CD90, and EpCAM CSC markers may be linked to HCC tumor onset and/or progression. In addition, EpCAM expression is associated with shorter survival time, while CD90 expression is associated with early HCC recurrence.
Author Zhe Guo Le-Qun Li Jing-Hang Jiang Chao Ou Li-Xia Zeng Bang-De Xiang
AuthorAffiliation Department of Hepatobiliary Surgery,Tumor Hospital of Guangxi Medical University Department of Clinical Laboratory,Tumor Hospital of Guangxi Medical University Department of Pathology,Tumor Hospital of Guangxi Medical University
Author_xml – sequence: 1
  givenname: Zhe
  surname: Guo
  fullname: Guo, Zhe
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24616575$$D View this record in MEDLINE/PubMed
BookMark eNp1kUtr3DAUhUVJaSZp190VLbvx5OplS5tCGfqCQDftWijy9YxSjzSR7An595XJJLSFCoRAOt85XJ0LchZTRELeMliLTuqr-9vt-shhHfSag9EvyIpzZhquJZyRFQPoGiN4d04uSrkF4EIo_oqcc9myVnVqRdzGRY-Zlgn31OM40r3LvzAX6lPOOLoJ6X2YdhRdHh9oRj_X64pQF3ta5nwMRzfSEOkOD25Ki8U8uky9yz7EtHevycvBjQXfnM5L8vPzpx-br8319y_fNh-vGy9FNzVDOygGDJDDoNuOsR5VhyhbZOAEk23XixupYRDC6FabqjNQNbIHJYUYxCX58Oh7mG_22HuMU3ajPeRQJ3qwyQX790sMO7tNRyuMkFKzavD-ZJDT3YxlsvtQlnlcxDQXyxS0nTZa8ip992fWc8jTv1aBehT4nErJOFgfJjeFtESH0TKwS3-29mdrfzZou_RXuat_uCfr_xPiROxS3N6FuH1GDOhlGQVSS6O41KqtGxQTvwFn9a-N
CitedBy_id crossref_primary_10_1038_cddis_2015_241
crossref_primary_10_18632_oncotarget_19000
crossref_primary_10_1007_s13277_016_4915_3
crossref_primary_10_1186_s12957_016_1028_9
crossref_primary_10_1186_s12967_020_02243_w
crossref_primary_10_3892_ol_2018_8666
crossref_primary_10_1155_2021_5546032
crossref_primary_10_1016_j_ijsu_2018_06_025
crossref_primary_10_1097_PAI_0000000000000840
crossref_primary_10_18632_oncotarget_10750
crossref_primary_10_3390_cancers16101831
crossref_primary_10_18097_PBMC20166203228
crossref_primary_10_1097_MD_0000000000001306
crossref_primary_10_1124_jpet_123_001898
crossref_primary_10_1007_s11605_020_04611_9
crossref_primary_10_1002_dvdy_24242
crossref_primary_10_3748_wjg_v24_i35_4000
crossref_primary_10_3390_cells9061331
crossref_primary_10_1097_01_XEJ_0000534710_66241_04
crossref_primary_10_3390_cells9041020
crossref_primary_10_1111_cas_13415
crossref_primary_10_1186_s12943_015_0426_x
crossref_primary_10_1007_s12672_025_02095_0
crossref_primary_10_1093_jjco_hyx157
crossref_primary_10_1016_j_livres_2023_07_003
crossref_primary_10_1016_j_amjsurg_2015_12_019
crossref_primary_10_18632_oncoscience_163
crossref_primary_10_1002_mc_22532
crossref_primary_10_1097_PAS_0000000000001990
crossref_primary_10_1016_j_tranon_2021_101073
crossref_primary_10_3390_medicina58020212
crossref_primary_10_4081_oncol_2020_452
crossref_primary_10_1016_j_bbrc_2020_03_009
crossref_primary_10_1111_jcmm_18295
crossref_primary_10_1016_j_biocel_2016_06_004
crossref_primary_10_3389_fonc_2020_572861
crossref_primary_10_18632_oncotarget_22078
crossref_primary_10_3748_wjg_v21_i42_12190
crossref_primary_10_18632_oncotarget_10807
crossref_primary_10_1007_s13277_015_3487_y
crossref_primary_10_5009_gnl18345
crossref_primary_10_1097_MD_0000000000001806
crossref_primary_10_3389_fonc_2023_1242231
crossref_primary_10_1111_his_13520
crossref_primary_10_3727_096504020X15919605976853
crossref_primary_10_1002_med_21967
crossref_primary_10_2217_epi_15_23
crossref_primary_10_1016_j_ajg_2020_04_002
crossref_primary_10_1080_0284186X_2019_1657940
crossref_primary_10_3892_ol_2016_4343
crossref_primary_10_18632_oncotarget_9116
crossref_primary_10_1134_S1990750817010036
crossref_primary_10_3390_cells9122672
crossref_primary_10_1007_s00595_020_01968_x
crossref_primary_10_1155_2018_5970852
crossref_primary_10_3892_ol_2016_4547
crossref_primary_10_3748_wjg_v25_i14_1653
crossref_primary_10_2147_OTT_S298576
crossref_primary_10_4254_wjh_v7_i1_7
crossref_primary_10_1016_j_talanta_2021_122817
crossref_primary_10_1186_s12967_015_0609_7
crossref_primary_10_1093_carcin_bgx050
crossref_primary_10_1007_s10620_019_05844_8
crossref_primary_10_1186_s13046_019_1442_2
crossref_primary_10_1016_j_clinre_2021_101664
crossref_primary_10_3390_ijms24021417
ContentType Journal Article
Copyright 2014 Baishideng Publishing Group Co., Limited. All rights reserved. 2014
Copyright_xml – notice: 2014 Baishideng Publishing Group Co., Limited. All rights reserved. 2014
DBID 2RA
92L
CQIGP
W91
~WA
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.3748/wjg.v20.i8.2098
DatabaseName 维普_期刊
中文科技期刊数据库-CALIS站点
中文科技期刊数据库-7.0平台
中文科技期刊数据库-医药卫生
中文科技期刊数据库- 镜像站点
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
DocumentTitleAlternate Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma
EISSN 2219-2840
EndPage 2106
ExternalDocumentID PMC3934481
24616575
10_3748_wjg_v20_i8_2098
90888889504849524856485051
Genre Research Support, Non-U.S. Gov't
Journal Article
Observational Study
GroupedDBID ---
123
29R
2B.
2C~
2RA
2WC
36B
53G
5VR
8WL
92F
92I
92L
93N
93R
AAKDD
ACGFO
AENEX
AFUIB
ALMA_UNASSIGNED_HOLDINGS
CCEZO
CHBEP
CIEJG
CQIGP
CS3
CW9
DIK
DU5
E3Z
EBS
EJD
EMB
F5P
FA0
FRP
GX1
HYE
M~E
OK1
P2P
RNS
RPM
SV3
TCJ
TGQ
TR2
W91
WFFXF
XSB
~WA
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c437t-f6f51010e20f86711de57ee46e10a31467d3b480f3398689e2090de54d05433f3
ISSN 1007-9327
2219-2840
IngestDate Thu Aug 21 18:11:55 EDT 2025
Fri Jul 11 11:42:48 EDT 2025
Mon Jul 21 05:50:35 EDT 2025
Thu Apr 24 22:53:21 EDT 2025
Tue Jul 01 01:53:29 EDT 2025
Wed Feb 14 10:28:37 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 8
Keywords Epithelial cell adhesion molecule
Hepatocellular carcinoma
Cancer stem cells
CD90
CD133
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c437t-f6f51010e20f86711de57ee46e10a31467d3b480f3398689e2090de54d05433f3
Notes Zhe Guo;Le-Qun Li;Jing-Hang Jiang;Chao Ou;Li-Xia Zeng;Bang-De Xiang;Department of Hepatobiliary Surgery,Tumor Hospital of Guangxi Medical University;Department of Clinical Laboratory,Tumor Hospital of Guangxi Medical University;Department of Pathology,Tumor Hospital of Guangxi Medical University
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
Telephone: +86-771-5330968 Fax: +86-771-5312000
Correspondence to: Bang-De Xiang, PhD, Department of Hepatobiliary Surgery, Tumor Hospital of Guangxi Medical University, He Di Rd. 71, Nanning 530021, Guangxi Zhuang Autonomous Region, China. xiaopushu-213@163.com
Author contributions: Xiang BD designed the research; Guo Z and Li LQ performed the research; Jiang JH and Guo Z evaluated the clinic records and performed the statistical analysis; Ou C and Zeng LX performed the immunohistochemistry experiment; Guo Z wrote the manuscript; all authors have read and approved the final manuscript.
OpenAccessLink https://www.wjgnet.com/1007-9327/full/v20/i8/2098.htm
PMID 24616575
PQID 1506789842
PQPubID 23479
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_3934481
proquest_miscellaneous_1506789842
pubmed_primary_24616575
crossref_citationtrail_10_3748_wjg_v20_i8_2098
crossref_primary_10_3748_wjg_v20_i8_2098
chongqing_primary_90888889504849524856485051
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2014-02-28
PublicationDateYYYYMMDD 2014-02-28
PublicationDate_xml – month: 02
  year: 2014
  text: 2014-02-28
  day: 28
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle World journal of gastroenterology : WJG
PublicationTitleAlternate World Journal of Gastroenterology
PublicationYear 2014
Publisher Baishideng Publishing Group Co., Limited
Publisher_xml – name: Baishideng Publishing Group Co., Limited
References 15567937 - Breast Cancer Res Treat. 2004 Aug;86(3):207-13
16678891 - Gynecol Oncol. 2006 Nov;103(2):483-8
7509044 - Nature. 1994 Feb 17;367(6464):645-8
21259248 - J Surg Oncol. 2011 Feb;103(2):148-51
21296855 - CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
17122772 - Nature. 2007 Jan 4;445(7123):106-10
19747749 - J Hepatol. 2009 Nov;51(5):890-7
19018978 - Liver Int. 2009 May;29(5):736-42
9802183 - Stat Med. 1998 Oct 15;17(19):2265-81
16256907 - J Am Coll Surg. 2005 Nov;201(5):663-70
20925139 - Pharm Stat. 2011 Mar-Apr;10(2):150-61
12409666 - Ann Surg. 2002 Nov;236(5):602-11
17952444 - Pediatr Surg Int. 2008 Jan;24(1):101-5
22161900 - J Surg Oncol. 2012 Jan;105(1):85-90
18275073 - Hepatology. 2008 Mar;47(3):919-28
23180689 - Int J Cancer. 2013 Jun 15;132(12):2948-55
18285265 - Am J Clin Pathol. 2008 Mar;129(3):424-9
14522905 - Cancer Res. 2003 Sep 15;63(18):5821-8
15888687 - Stem Cells. 2005 Aug;23(7):879-94
17600130 - Am J Pathol. 2007 Aug;171(2):386-95
19150350 - Gastroenterology. 2009 Mar;136(3):1012-24
19711346 - Int J Cancer. 2010 May 1;126(9):2067-78
23504121 - Ann Surg Oncol. 2013 Aug;20(8):2526-33
21374666 - Hepatology. 2011 Mar;53(3):1020-2
22799330 - Asian Pac J Cancer Prev. 2012;13(4):1349-53
18172261 - Clin Cancer Res. 2008 Jan 1;14(1):123-9
9356465 - Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12425-30
17097610 - Biochem Biophys Res Commun. 2006 Dec 29;351(4):820-4
17211480 - Br J Cancer. 2007 Feb 12;96(3):417-23
17673212 - Gastroenterology. 2007 Sep;133(3):937-50
11259604 - Mol Cell Biol. 2001 Apr;21(7):2570-80
16076007 - Surgeon. 2005 Jun;3(3):210-5
11689955 - Nature. 2001 Nov 1;414(6859):105-11
22237392 - Nat Rev Cancer. 2012 Feb;12(2):133-43
22080056 - Mod Pathol. 2012 Mar;25(3):456-64
17122771 - Nature. 2007 Jan 4;445(7123):111-5
20602260 - Ann Surg Oncol. 2010 Dec;17(12):3137-44
15608167 - Nucleic Acids Res. 2005 Jan 1;33(Database issue):D154-9
18923165 - N Engl J Med. 2008 Nov 6;359(19):1995-2004
19190964 - Ann Surg Oncol. 2009 Apr;16(4):792-4
17585167 - Stem Cells. 2007 Oct;25(10):2575-82
18356041 - Curr Opin Genet Dev. 2008 Feb;18(1):48-53
19136966 - Nat Cell Biol. 2009 Feb;11(2):162-71
19583834 - J Transl Med. 2009;7:56
10077043 - Ann Surg. 1999 Mar;229(3):322-30
References_xml – reference: 17211480 - Br J Cancer. 2007 Feb 12;96(3):417-23
– reference: 18923165 - N Engl J Med. 2008 Nov 6;359(19):1995-2004
– reference: 19018978 - Liver Int. 2009 May;29(5):736-42
– reference: 17600130 - Am J Pathol. 2007 Aug;171(2):386-95
– reference: 19583834 - J Transl Med. 2009;7:56
– reference: 17122771 - Nature. 2007 Jan 4;445(7123):111-5
– reference: 10077043 - Ann Surg. 1999 Mar;229(3):322-30
– reference: 19150350 - Gastroenterology. 2009 Mar;136(3):1012-24
– reference: 19747749 - J Hepatol. 2009 Nov;51(5):890-7
– reference: 22799330 - Asian Pac J Cancer Prev. 2012;13(4):1349-53
– reference: 12409666 - Ann Surg. 2002 Nov;236(5):602-11
– reference: 16678891 - Gynecol Oncol. 2006 Nov;103(2):483-8
– reference: 18356041 - Curr Opin Genet Dev. 2008 Feb;18(1):48-53
– reference: 18275073 - Hepatology. 2008 Mar;47(3):919-28
– reference: 15567937 - Breast Cancer Res Treat. 2004 Aug;86(3):207-13
– reference: 17585167 - Stem Cells. 2007 Oct;25(10):2575-82
– reference: 16256907 - J Am Coll Surg. 2005 Nov;201(5):663-70
– reference: 17122772 - Nature. 2007 Jan 4;445(7123):106-10
– reference: 19136966 - Nat Cell Biol. 2009 Feb;11(2):162-71
– reference: 11689955 - Nature. 2001 Nov 1;414(6859):105-11
– reference: 21259248 - J Surg Oncol. 2011 Feb;103(2):148-51
– reference: 22161900 - J Surg Oncol. 2012 Jan;105(1):85-90
– reference: 22080056 - Mod Pathol. 2012 Mar;25(3):456-64
– reference: 9356465 - Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12425-30
– reference: 9802183 - Stat Med. 1998 Oct 15;17(19):2265-81
– reference: 22237392 - Nat Rev Cancer. 2012 Feb;12(2):133-43
– reference: 19190964 - Ann Surg Oncol. 2009 Apr;16(4):792-4
– reference: 19711346 - Int J Cancer. 2010 May 1;126(9):2067-78
– reference: 17097610 - Biochem Biophys Res Commun. 2006 Dec 29;351(4):820-4
– reference: 18172261 - Clin Cancer Res. 2008 Jan 1;14(1):123-9
– reference: 21296855 - CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
– reference: 7509044 - Nature. 1994 Feb 17;367(6464):645-8
– reference: 18285265 - Am J Clin Pathol. 2008 Mar;129(3):424-9
– reference: 23504121 - Ann Surg Oncol. 2013 Aug;20(8):2526-33
– reference: 21374666 - Hepatology. 2011 Mar;53(3):1020-2
– reference: 11259604 - Mol Cell Biol. 2001 Apr;21(7):2570-80
– reference: 17673212 - Gastroenterology. 2007 Sep;133(3):937-50
– reference: 17952444 - Pediatr Surg Int. 2008 Jan;24(1):101-5
– reference: 15888687 - Stem Cells. 2005 Aug;23(7):879-94
– reference: 14522905 - Cancer Res. 2003 Sep 15;63(18):5821-8
– reference: 15608167 - Nucleic Acids Res. 2005 Jan 1;33(Database issue):D154-9
– reference: 23180689 - Int J Cancer. 2013 Jun 15;132(12):2948-55
– reference: 20602260 - Ann Surg Oncol. 2010 Dec;17(12):3137-44
– reference: 20925139 - Pharm Stat. 2011 Mar-Apr;10(2):150-61
– reference: 16076007 - Surgeon. 2005 Jun;3(3):210-5
SSID ssj0023352
Score 2.3799117
Snippet AIM:To investigate whether expression of cancer stem cell(CSC)markers is associated with recurrence and survival in hepatocellular...
To investigate whether expression of cancer stem cell (CSC) markers is associated with recurrence and survival in hepatocellular carcinoma (HCC) patients. A...
To investigate whether expression of cancer stem cell (CSC) markers is associated with recurrence and survival in hepatocellular carcinoma (HCC) patients.AIMTo...
AIM: To investigate whether expression of cancer stem cell (CSC) markers is associated with recurrence and survival in hepatocellular carcinoma (HCC) patients....
SourceID pubmedcentral
proquest
pubmed
crossref
chongqing
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2098
SubjectTerms AC133 Antigen
Adult
Antigens, CD - metabolism
Antigens, Neoplasm - metabolism
Brief
Cancer
carcinoma
Carcinoma, Hepatocellular - pathology
Carcinoma, Hepatocellular - surgery
Case-Control Studies
CD133
Cell Adhesion Molecules - metabolism
cells
Cohort Studies
Disease Progression
Epithelial Cell Adhesion Molecule
Follow-Up Studies
Glycoproteins - metabolism
Hepatectomy
Hepatocellular
Humans
Immunohistochemistry
Liver - metabolism
Liver Neoplasms - pathology
Liver Neoplasms - surgery
Middle Aged
Neoplasm Recurrence, Local
Neoplastic Stem Cells - cytology
Peptides - metabolism
Prognosis
stem
Thy-1 Antigens - metabolism
Treatment Outcome
Title Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma
URI http://lib.cqvip.com/qk/84123X/201408/90888889504849524856485051.html
https://www.ncbi.nlm.nih.gov/pubmed/24616575
https://www.proquest.com/docview/1506789842
https://pubmed.ncbi.nlm.nih.gov/PMC3934481
Volume 20
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELaq5cIFgXiVl4zEAamkpLGT2EdUAVUFCKRdseISJanTFu0mJU0WiR_Fb2TGdty0u0iwlRq1qe2oni-eR8bfEPIiiBdMBQrub7AGPCx176UyzD0W-QXPfRXyTGf5fopmJ3x-Gp4OBr97WUttk43zX1fuK7mOVOEcyBV3yf6HZN2gcAI-g3zhCBKG4z_JeIoiq0fIxTzCCPzoHJNt6u0ox5obZ2BGmjir0izGNYbWDamsjpa3sEpcaM4NMBc34HzjEDorNccCQ2Vll2xrupq0mx7TxDLdNnWFnJ61IXLC6MLXuSvW9b7VYdhvK4edD2YrtvK-tA6T87WNWM9BiXqz1GpSjPu2Nh-g6ocmJry31VvH37CANJZGXV6KqcFqNzaBh4NdXJi04YFNGfdX6MDvIVH0l1vflLC2qhvc1-gqtYAUOyDLn9-X44vAH68xpc907IFkc65Rgvx6-DBqpx9d1uLnj1MmGfiz4G3fCMAtYV10yDr4uH9NP123_8FQSeHVXx9cGzmo7YWQ1GNVlcsfMDn7xtElj-cwcbdnCR3fJresC0PfGDzeIQNV3iWpwSJFLFIEErVYpA6LFLFINRbpDosUsEg7LNJ1SfexSB0W75GTd2-PpzPPlu_wcs7ixiuiAhd8XwV-gSyKk4UKY6V4pCZ-ylBDL1jGhV8wJkUkJLSTPrThC3AjGCvYfXJUVqV6SKiUhRAZeAIq4zzP4GsueC6LTIC7vAjTIXnl5jDZGJqWBDP44CVDUFJchsjdF8EbtNCQjLtpTnJLhY8VWc4ScIlRXAmIKwFxJWuRoLiG5KXr0A3_16bPO7klsFLjbKWlqtptglyesZCCB0PywMjRDdaBYUjiPQm7BsgCv_9LuV5pNngLyUfX7vmY3NzdvE_IUVO36ilY2k32TMP7D2gv1zs
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cancer+stem+cell+markers+correlate+with+early+recurrence+and+survival+in+hepatocellular+carcinoma&rft.jtitle=World+journal+of+gastroenterology+%3A+WJG&rft.au=Guo%2C+Zhe&rft.au=Li%2C+Le-Qun&rft.au=Jiang%2C+Jing-Hang&rft.au=Ou%2C+Chao&rft.date=2014-02-28&rft.pub=Baishideng+Publishing+Group+Co.%2C+Limited&rft.issn=1007-9327&rft.volume=20&rft.issue=8&rft.spage=2098&rft.epage=2106&rft_id=info:doi/10.3748%2Fwjg.v20.i8.2098&rft_id=info%3Apmid%2F24616575&rft.externalDocID=PMC3934481
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F84123X%2F84123X.jpg